NanOlogy touted results today from preclinical studies of its inhaled submicron particle formulation of paclitaxel, NanoPac.
The company said animal studies have shown prolonged retention of the cancer drug in lung tissue and significant tumor regression without adverse drug-related side effects.
Get the full story at our sister site, Drug Delivery Business News.
The post NanOlogy touts preclinical data for inhaled NanoPac cancer drug appeared first on MassDevice.